Physician profile
Taylor Wade
NPI 1710464482
$2,044.76
in general payments reported to CMS, 2019-2025
20 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.55 · 2021: $217 · 2022: $477 · 2023: $469 · 2024: $339 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,295.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $331.64 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $267.68 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $179.99 | 2021-2025 | Ubrelvy, Qulipta |
| Astellas Pharma US INC | $176.45 | 2023-2025 | Veozah, Myrbetriq |
| Novo Nordisk INC | $169.17 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $157.17 | 2021-2025 | Breztri, Farxiga |
| Pfizer INC. | $120.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $118.39 | 2019-2024 | Shingrix, Bexsero, Arexvy |
| Novartis Pharmaceuticals Corporation | $87.74 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $79.42 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $77.22 | 2022-2023 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $61.19 | 2023-2025 | Xifaxan, Trulance |
| Idorsia Pharmaceuticals US INC | $53.19 | 2022-2023 | Quviviq |
| Insulet Corporation | $46.56 | 2025 | Omnipod |
| Amgen INC. | $46.55 | 2022-2025 | Prolia, Evenity |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $16.12 | 2023 | Dexcom G6 Transmitter |
| Lundbeck LLC | $14.52 | 2023 | Vyepti |
| Boston Scientific Corporation | $14.02 | 2024 | Intracept |
| Medtronic, INC. | $13.79 | 2023 | Minimed 780g |
| Sanofi-Aventis U.S. LLC | $13.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.